Clinical Trials on Micrometastasis Breast Cancer

Total 54300 results

National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Terminated

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Triple Negative Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Negative Breast Cancer

United States
Dana-Farber Cancer Institute
Genentech, Inc.

Active, not recruiting

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Breast Cancer | Stage II Breast Cancer | HER-2 Positive Breast Cancer | Stage III Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
European Institute of Oncology

Recruiting

fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases (fREEDOM)

Triple Negative Breast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer

Italy
Akeso

Recruiting

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Metastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast Cancer

China
Dana-Farber Cancer Institute
Johns Hopkins University; GlaxoSmithKline; Translational Breast Cancer Research...

Recruiting

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | HER2-negative Breast Cancer | Stage III Breast Cancer | Deleterious PALB2 Gene Mutation | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene Mutation

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Puerto Rico
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Fudan University

Not yet recruiting

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
Fudan University

Recruiting

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Triple-Negative Breast Cancer

China
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
Shanghai Proton and Heavy Ion Center

Recruiting

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

Triple Negative Breast Cancer | HER2-positive Breast Cancer

China
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China
H. Lee Moffitt Cancer Center and Research Institute
The Shulas' Foundation

Recruiting

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)

Triple Negative Breast Cancer | HER2-negative Breast Cancer

United States
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China
Kasr El Aini Hospital

Not yet recruiting

Neoadjuvant Goserelin for Triple Negative Breast Cancer (NeoGONT)

Breast Cancer Triple Negative
German Breast Group
Gilead Sciences; ETOP IBCSG Partners Foundation; UNICANCER; Austrian Breast & Colorectal... and other collaborators

Active, not recruiting

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA)

Triple Negative Breast Cancer | HER2-negative Breast Cancer

France, Spain, Germany, Switzerland, Austria, Ireland, Belgium
Hoffmann-La Roche

Completed

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131)

Triple-Negative Breast Cancer

France, Canada, Israel, Italy, Argentina, Brazil, China, Croatia, Germany, Greece, Slovakia, Turkey, Saudi Arabia, Japan, India, Spain, United States, Czechia, Romania, United Kingdom, Morocco, South Africa, Vietnam, Russian Federation
Gilead Sciences

Active, not recruiting

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

Triple-Negative Breast Cancer

United States, United Kingdom, Australia, Hong Kong, Korea, Republic of, Taiwan
Palleos Healthcare GmbH
Roche Pharma AG; University Hospital, Essen; University Hospital Erlangen; Phaon...

Active, not recruiting

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)

Triple-negative Breast Cancer

Germany
NYU Langone Health

Completed

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Breast Cancer

United States
Samsung Medical Center

Active, not recruiting

Exosome as the Prognostic and Predictive Biomarker in EBC Patients

Triple Negative Breast Cancer | HER2-positive Breast Cancer

Korea, Republic of
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

BRCA and NACT in TNBC Patients (Light-Bright)

Triple-Negative Breast Cancer

Italy
Novartis Pharmaceuticals

Completed

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Triple-negative Breast Cancer

Belgium, Italy, Japan, Taiwan, United States, Australia, Singapore, Spain, Germany, Korea, Republic of, Argentina, Canada, France, Hungary, Israel, Lebanon, Thailand
Guangdong Provincial People's Hospital
First Affiliated Hospital, Sun Yat-Sen University; Henan Cancer Hospital; Dongguan... and other collaborators

Completed

DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

China
NuGenerex Immuno-Oncology
Merck Sharp & Dohme LLC; NSABP Foundation Inc

Active, not recruiting

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)

Triple-negative Breast Cancer

United States
Priyanka Sharma

Completed

Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer (NeoSTOP)

Triple-negative Breast Cancer

United States
Henan Cancer Hospital

Unknown

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy...

Unknown

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Gateway for Cancer Research

Active, not recruiting

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB... and other conditions

United States
University of Pennsylvania

Active, not recruiting

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

Breast Neoplasm | Metastatic Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC

Completed

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy)

Male Breast Cancer | Breast - Female

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Veronica Morgan Jones

Recruiting

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Breast Cancer | Breast Carcinoma | HER2-negative Breast Cancer | Node-negative Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Breast Inflammatory Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IB Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients

Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III

United States
Hoffmann-La Roche

Completed

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

HER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer | Hereditary Breast/Ovarian Cancer - BRCA1 | Hereditary Breast/Ovarian Cancer...

United States
Merrimack Pharmaceuticals
Sanofi

Completed

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

ER Positive, Her2 Negative Breast Cancer Patients | Triple Negative Breast Cancer Patients

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.

Lymphedema | Stage II Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Recurrent Breast Cancer

United States
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
Carrick Therapeutics Limited
Pfizer

Recruiting

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC)

Breast Cancer | Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain, United States, Turkey, Hungary
Dana-Farber Cancer Institute
Johns Hopkins University; National Cancer Institute (NCI); Gateway for Cancer... and other collaborators

Recruiting

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer

United States
Fudan University

Recruiting

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Metastatic Breast Cancer | HER2-positive Breast Cancer

China

Clinical Trials on Micrometastasis Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations